Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Blueprint Medicines Corp (BPMC) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/27/2023 8-K Investor presentation
Docs: "INTRODUCTION CHIEF EXECUTIVE OFFICER BLUEPRINT MEDICINES KATE"
01/09/2023 8-K Investor presentation
Docs: "KATE HAVILAND, PRESIDENT AND CEO J.P. MORGAN HEALTHCARE CONFERENCE"
09/07/2022 8-K Investor presentation
Docs: "BLUEPRINT MEDICINES COMPANY OVERVIEW SEPTEMBER 2022"
06/30/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
01/10/2022 8-K Investor presentation
Docs: "OUR FIRST DECADE OF ACHIEVEMENT",
"Investor Contact"
01/11/2021 8-K Quarterly results
04/01/2020 8-K Investor presentation
01/13/2020 8-K Investor presentation
11/05/2019 8-K Investor presentation, Quarterly results
Docs: "Sr. Manager, Investor Relations",
"w e l c o m e JEFF ALBERS Chief Executive Officer"
06/03/2019 8-K Investor presentation
Docs: "Blueprint Medicines Presents NAVIGATOR Trial Data in PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST at ASCO 2019 Supporting Planned Marketing Applications for Avapritinib",
"Presentation by Blueprint Medicines Corporation for avapritinib in advanced GIST at the ASCO Annual Meeting on June 1, 2019",
"Blueprint Medicines’ Highly Selective RET Inhibitor BLU-667 Shows Durable Anti-Tumor Activity in Patients with RET-Altered Cancers in Updated ARROW Trial Data Presented at ASCO 2019",
"Presentation by Blueprint Medicines Corporation for BLU-667 in RET-mutant MTC and other RET-altered cancers at the ASCO Annual Meeting on June 1, 2019",
"Presentation by Blueprint Medicines Corporation for BLU-667 in RET-fusion NSCLC at the ASCO Annual Meeting on June 3, 2019"
10/01/2018 8-K Quarterly results
06/15/2018 8-K Investor presentation
Docs: "Blueprint Medicines Announces Updated Data from Ongoing Phase 1 EXPLORER Clinical Trial of Avapritinib in Patients with Advanced Systemic Mastocytosis Showing Profound and Durable Clinical Activity – Overall Response Rate of 83% –",
"Poster presentation by Blueprint Medicines Corporation on June 15, 2018 at the Congress of the European Hematology Association"
12/05/2016 8-K Form 8-K - Current report
11/30/2016 8-K Investor presentation
Docs: "Press release issued by Blueprint Medicines Corporation on November 30, 2016",
"Poster presentation by Blueprint Medicines Corporation on November 29, 2016 at the EORTC-NCI-AACR Symposium"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy